Three commercial indirect enzyme-linked immunosorbent assays (ELISAs) (RUBELISA, EnzygnostRubella, and Rubazyme) and a commercial single radial hemolysis (SRH) test (Rubazone) were evaluated for the diagnosis of acute rubella by testing 41 acute-(<7 days postonset) and convalescent-phase (8 to 82 days postonset) serum pairs from cases of rubella previously confirmed by signfficant change in the hemagglutination inhibition test titer. Specificity was tested by using 10 acute-and convalescent-phase serum samples from patients with rash not confirmed as rubella (control group 
Since 1967 diagnosis of rubella infection has been carried out mainly by serological means by the hemagglutination inhibition test (HAI). This has been done by demonstrating fourfold or greater rises in HAI titers between paired serum specimens; however, in cases where an acute-phase blood specimen is not available, and it is not possible to demonstrate a rise in antibody titer, specific immunoglobulin M (IgM) antibody testing has been done by separating the IgM fraction of serum from IgG and testing this fraction for rubella HAI antibody activity (24) . The isolation of rubella virus is seldom used, as a diagnosis of rubella is obtained more readily by serological testing (12) .
During recent years several other techniques have been described for the measurement of rubella IgG or IgM antibody, or both. Antibody measured by passive hemagglutination (3) is not of the IgM class and shows a considerably delayed immune response and, owing to the urgency of rapid diagnosis of rubella infection in pregnant women, demonstration of seroconversion by this technique is impractical. Single radial haemolysis (SRH) (21) provides a simple means for confirmation of recent rubella by showing an increase in antibody level in paired serum specimens, but it cannot be used to detect IgM antibody (13) .
On the other hand, enzyme-linked immunosorbent assay (ELISA) (23) and solid-phase radioimmunoassay (16) (4, 11, 13, 19, 21) , but only brief mention has been made of the use of commercial reagents for such purpose (22) . (i) Confirmed rubella infection group. Paired serum specimens were collected from 41 patients during the acute and convalescent stages of rubella infection (patients 1 through 41). These cases were confirmed as rubella by demonstration of seroconversion or significant rise in antibody titer as determined by HAI. In two cases three additional serum specimens were collected, so that a total of 85 specimens was tested. It was not possible to determine the exact date of onset of symptoms for some patients, but in all cases the collection of the acute-phase serum specimens was within 1 week of onset. Convalescent-phase serum specimens were collected at periods ranging from 8 to 82 days after onset, but mainly in the second and third weeks after onset.
(ii) Control group. Paired serum specimens were collected from 10 patients during the acute and convalescent stages of an illness resembling rubella (patients 42 er; Dynatech Laboratories, Inc., Alexandria, Va.). For Rubazyme, washing was done with a Pentawash 1I (Abbott Laboratories) and absorbances were measured in a Quantum II spectrophotometer (Abbott Laboratories).
The methods for evaluating the results for paired serum samples for the presence of a significant increase in rubella IgG appear in detail as footnotes to Table 4. SRH test. All sera were tested with commercial reagents (Rubazone; Scientific Measuring Instruments, Sydney, Australia). Serum samples (5 jl), inactivated at 56°C, were added to wells in a system that was similar to that described by Vaananen and Vaheri (21) , except that sheep erythrocytes were used and complement was added to the plates after overnight radial diffusion of IgG antibody. To minimize interlaboratory variability, a standard curve was produced by using calibrators standardized against the World Health Organization 1,000-IU standard for anti-rubella serum, and all SRH titers were expressed in international units. Fourfold increases in antibody level indicated suspected current infection.
ELISA for rubella IgM. All serum specimens were tested for rubella IgM antibody by three indirect ELISA systems with commercial reagents. The reagents used were RU-BELISA M, Enzygnost-Rubella (Behringwerke, Marburg, West Germany), and Rubazyme-M.
All the test systems used the principal of indirect ELISA. and the procedure used was that recommended by the manufacturer. The shortened enzyme action time, which was found necessary in the Enzygnost-Rubella IgG ELISA, was not required in the IgM ELISA. The principal differences in methods among the three tests systems are shown in Table 2 .
The solid-phase component of each system, the method of washing, and the absorbance reading were similar to that described for the IgG ELISA. All systems used an antihuman IgM conjugate. Comparison of the three ELISA methods for detection of rubella IgM antibody in acute-and convalescent-phase serum specimens. To determine whether acute-phase serum specimens could be used to obtain an early and hence rapid diagnosis, the 42 acute-phase serum specimens (collected <7 days after onset) were compared with the 43 convalescentphase serum specimens (collected .7 days after onset) obtained from the 41 cases of confirmed rubella infection (Table 5) .
Of The overall detection rate of rubella IgM antibody by using the three ELISA methods with the 85 serum specimens from the confirmed rubella infection group (acute-and convalescent-phase specimens combined) was 58 (68.2%) for RUBELISA M, 62 (72.9%) for Enzygnost-Rubella, and 51 (60%) for Rubazyme-M. Equivocal results were obtained with four serum specimens tested by RUBELISA M (patients 20, 32, 40, and 41) and two serum specimens tested by Rubazyme-M (patients 4 and 31).
In the group with rash not confirmed as rubella (control group) 2 of 20 serum specimens (10%) were positive by Rubazyme-M (Table 5 ). These two specimens were acuteand convalescent-phase sera from patient 44. No falsepositive results were obtained with either RUBELISA M or Enzygnost-Rubella.
Persistence of rubella-specific IgM. Enzygnost-Rubella detected rubella-specific IgM in all sera collected between 7 and 82 days. RUBELISA M detected specific IgM in all such sera up to 63 days after onset (patient 40). At 82 days (patient 41) this test gave an equivocal result which was just below the positive cut-off point (Table 4) . Rubazyme-M was reliable in detecting rubella-specific IgM up to 26 days after onset (patient 33) but detected this antibody irregularly thereafter. For example, Rubazyme-M was negative at 28 days (patient 34), 29 days (patient 36), and 63 days (patient 40), but on the other hand, it detected rubella IgM in a different patient (patient 35) at 28 days. It also was positive at 30 days (patient 37), 35 days (patient 38), 36 days (patient 39), and 82 days (patient 41).
It should be pointed out that the serum collected from patient 17 at 15 days after onset was an exception to the above in that none of the three ELISA systems detected rubella IgM, despite the fact that significant rises in antibody level were shown in this patient by HAI, SRH, RUBELISA, Enzygnost-Rubella, and Rubazyme. Other investigators (4, 20, 23, 25) have found that enzyme immunoassay detects rising levels of rubella IgG antibody later in the course of infection than the HAI test, and this may in fact be an advantage in the diagnosis of some infections where the first serum specimen is drawn late and a rise in HAI antibodies cannot be shown. However, this was not seen in the present study, as acute-phase serum specimens were collected early in the first week after onset of infection. As SRH detects only IgG antibody, the advantages in relation to the timing of collection of specimens are the same (21) as for IgG ELISA.
Rubella-specific IgM was detected in 29 to 48% of acutephase serum specimens from confirmed rubella cases, depending on the ELISA method used, and thus there appears to be a limit to the use of these tests for rapid diagnosis on single acute-phase serum specimens. However, the acutephase serum specimens tested in this study were collected within 2 to 3 days of the onset of a rash, and this may explain why higher detection rates of specific IgM were not obtained. Other reports have also indicated that rapid diagnosis by estimating specific IgM in acute-phase serum specimens is limited. For example, Coxiella burnetii-specific IgM was detected by ELISA in only 4% of the acute-phase serum specimens collected during the first week after onset of Q fever infection and in 38% of the serum specimens collected during the second week (7) . In another study (C. was no other evidence that this patient was undergoing a secondary infection. The possibility of hypogammaglobulinemia was ruled out, as total immunoglobulin levels were shown to be normal. Alternatively, the IgM response may have been of very short duration.
In the control group, the two false-positive results detected by Rubazyme-M are of concern. It has been shown that Rubazyme-M can produce false-positive results due to the presence of heterophil antibodies (18) , but the manufacturer claims that false-positive results only occurred in early Rubazyme-M kits and not in subsequently modified kits. The kits used in the present study were of the latter type. Despite continuous improvements being made, a later study (2) In many kits the identity of some of the reagents is not revealed, and this applies to the test systems evaluated in this communication. It has been suggested that no clinical chemist should ever agree to employ secret reagents (6) . It is appreciated that companies expend much effort in producing reagent systems in competition with rival manufacturers and that, accordingly, they may not wish to make known some details of such systems. However, until more detailed information on the ingredients used is available from manufacturers, many reputable microbiologists will be reluctant to use such commercial reagent sets.
For the diagnosis of rubella when acute-and convalescentphase serum pairs are available, two commercial rubella IgG ELISA systems, Enzygnost-Rubella and Rubazyme, appeared to be suitable alternatives to the more laborious, yet well-proven and understood, HAI test. RUBELISA G did not detect infection in one patient. The commercial SRH, Rubazone, although the simplest test to perform, was the least satisfactory, as it failed to detect seroconversion in two patients and gave a false-positive result in another patient.
Of the three commercial ELISA systems tested for rubel- It is essential that all available evidence (all serological results, previous test results, and as much accurate clinical data as possible) be taken into consideration before making a diagnosis of rubella when this occurs in pregnancy. When the result is difficult to interpret or results are not consistent with the history, we would recommend that the tests be repeated and that sera giving equivocal results should be tested in a different assay.
